Why the study?
Despite high ASCVD risk and incidental CAC on screening LDCT, a substantial proportion of LCS-eligible individuals are not prescribed primary preventive statin therapy.
What is the frequency of statin prescription among lung cancer screening patients with moderate coronary artery calcifications?
What is the frequency of statin prescription among lung cancer screening patients with moderate coronary artery calcifications?
A significant proportion of lung cancer screening patients with moderate coronary artery calcifications and high ASCVD risk remain untreated with statins, highlighting a missed opportunity for primary prevention.
Statin underprescription persists in high-risk LCS patients with CAC; leaves open whether routine CAC reporting improves uptake.
Individuals eligible for lung cancer screening (LCS) are at risk for atherosclerotic cardiovascular disease (ASCVD) due to smoking history. Coronary artery calcifications (CAC), a common incidental finding on low-dose CT (LDCT) for LCS, is a predictor of cardiovascular events. Despite findings of high ASCVD risk and CAC, a substantial proportion of LCS patients are not prescribed primary preventive statin therapy for ASCVD. We assessed the frequency of statin prescription in LCS patients with moderate levels of CAC. Among 259 individuals with moderate CAC, 95% had ASCVD risk ≥ 7.5%. Despite this, 27% of patients were statin-free prior to LDCT and 21.2% remained statin-free after LDCT showing moderate CAC. Illustratively, while a substantial proportion of LCS patients are statin-eligible, many lack a statin prescription, even after findings of CAC burden. CAC reporting should be standardized, and interdisciplinary communication should be optimized to ensure that LCS patients are placed on appropriate preventive therapy.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: